Resources from the same session
LBA58 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
Presenter: Florence Duffaud
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA59 - LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
Presenter: Patricia Pautier
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
1520O - REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Presenter: Javier Martin Broto
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
1521O - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)
Presenter: Yuki Kojima
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Robin Jones
Session: Proffered Paper session - Sarcoma
Resources:
Slides
Webcast
Invited Discussant 1520O and 1521O
Presenter: Sebastian Bauer
Session: Proffered Paper session - Sarcoma
Resources:
Slides
Webcast
Invited Discussant LBA58 and LBA59
Presenter: Robin Jones
Session: Proffered Paper session - Sarcoma
Resources:
Slides
Webcast